FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

@article{Acquaviva2014FGFR3TI,
  title={FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.},
  author={Jaime Acquaviva and Suqin He and Chaohua Zhang and Jose Carlos Jimenez and Masazumi Nagai and Jim Sang and Manuel Sequeira and Donald L. Smith and Luisa Shin Ogawa and Takayo Inoue and Noriaki Tatsuta and Margaret A Knowles and Richard C. Bates and David A. Proia},
  journal={Molecular cancer research : MCR},
  year={2014},
  volume={12 7},
  pages={
          1042-54
        }
}
UNLABELLED Activating mutations and/or overexpression of FGFR3 are common in bladder cancer, making FGFR3 an attractive therapeutic target in this disease. In addition, FGFR3 gene rearrangements have recently been described that define a unique subset of bladder tumors. Here, a selective HSP90 inhibitor, ganetespib, induced loss of FGFR3-TACC3 fusion protein expression and depletion of multiple oncogenic signaling proteins in RT112 bladder cells, resulting in potent cytotoxicity comparable with… CONTINUE READING
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges

  • E di Martino, DC Tomlinson, MA. Knowles
  • Adv Urol ;:429213
  • 2012
2 Excerpts

Similar Papers

Loading similar papers…